Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Posted by Linda Flegge on Mar 23rd, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $10.13, for a total transaction of $20,260.00. Following the transaction, the president now owns 2,827,018 shares in the company, valued at approximately $28,637,692.34. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.09, for a total value of $24,180.00.
On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total value of $24,620.00.
On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total transaction of $23,480.00.
On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00.
On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.

Gyre Therapeutics Price Performance

Shares of NASDAQ:GYRE opened at $9.71 on Friday. The company’s 50-day moving average is $11.31 and its 200 day moving average is $12.20. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The company had revenue of $27.87 million during the quarter, compared to analysts’ expectations of $23.50 million.

Analyst Ratings Changes

Separately, Noble Financial assumed coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating on the stock.

Check Out Our Latest Research Report on GYRE

Institutional Trading of Gyre Therapeutics

Large investors have recently bought and sold shares of the company. FMR LLC bought a new position in shares of Gyre Therapeutics during the 3rd quarter worth $47,000. Wells Fargo & Company MN grew its stake in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after buying an additional 913 shares in the last quarter. Bank of America Corp DE raised its holdings in Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares during the period. Barclays PLC boosted its holdings in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after purchasing an additional 1,389 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.